UCUmberto Caterino

Umberto Caterino

*This is an algorithmically generated author record based on publicly available information.

Umberto Caterino has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic value of narrow-band imaging in suspected lung cancer: a single-centre observational study

    by Massimiliano Caterino, Cristiano Cesaro, Umberto Masi, Dupuis Diego, Dario Amore, Alfonso Fiorelli, Umberto Caterino

    Narrow-band imaging (NBI) enhances mucosal and vascular contrast during bronchoscopy and may support the detection of malignant airway lesions, although its specific diagnostic role in routine practice is still being defined. This single-centre retrospective observational study evaluated the relationship between NBI vascular patterns and histological diagnosis in 49 patients undergoing bronchoscopy for suspected lung cancer. Vascular patterns were classified as normal, dotted, abrupt-ending, or tortuous; dotted, abrupt-ending, and tortuous patterns were collectively considered pathological. Malignancy was confirmed in 34 patients (69.4%). Pathological vascular patterns were observed in 28 malignant cases and in three non-malignant cases, whereas normal patterns were present in six malignant and 12 non-malignant cases, corresponding to a sensitivity of 82.4%, specificity of 80.0%, positive predictive value of 90.3%, and negative predictive value of 66.7%. Pathological patterns were significantly associated with malignant histology (p < 0.001). Some numerical differences in the distribution of individual pathological patterns across histological subtypes were considered exploratory only. In conclusion, pathological NBI vascular patterns were significantly associated with malignant disease and demonstrated good diagnostic performance as an adjunct to white-light bronchoscopy. NBI should be regarded as a complementary tool for lesion assessment and biopsy guidance, while histopathological confirmation remains essential.

  • Open Access

    Treatment of benign endobronchial tumors: when, how, and why. Insights, experiences, and interventional pulmonology strategies

    by Cristiano Cesaro, Umberto Masi, Ilaria Pedicelli, Raffaella Lucci, Flavio Cesaro, Dario Amore, Roberta Cianci, Fabio Perrotta, Enzo Zamparelli, Umberto Caterino

    Benign endobronchial tumors are rare clinical entities characterized by considerable variability in etiology and clinical presentation. The authors report four cases of endobronchial hamartomas treated and followed up from 2018 to 2023. Three of these cases, with identical endobronchial localization in the right lower lobe, were radically treated in flexible bronchoscopy with only the use of biopsy forceps. Another case with a different localization in the left main bronchus was treated with a laser through rigid bronchoscopy. In addition, the authors outline the main interventional pulmonological strategies for the treatment of benign tumors with endobronchial growth based on the existing literature.


  • Open Access

    Comments on “The surgical approach of late-onset tracheoesophageal fistula in a tracheostomized COVID-19 patient”

    by Dario Amore, Marco Rispoli, Umberto Caterino, Dino Casazza, Pasquale Imitazione, Alessandro Saglia, Cristiano Cesaro

    Dear Editor, we have read with interest the case reported by Rotolo et al. (published in February 2023 as Early Access) concerning the surgical management of tracheoesophageal fistula (TEF) in a COVID-19 patient treated with prolonged mechanical ventilation for severe respiratory failure.


  • Bite Damage to the Rigid Bronchoscope

    by Cristiano Cesaro, Umberto Caterino, Francesco Aprn Rossi, Umberto Masi, Fabio Perrotta, Enzo Zamparelli, Flavio Cesaro, Alfonso Fiorelli

  • Open Access

    Transbronchial needle aspiration in severe cardiac failure patient: ‘The old bull knows best’

    by Umberto Caterino, Cristiano Cesaro, Raffaella Lucci, Flavio Cesaro, Umberto Masi, Alessandra Cotroneo, Dario Amore

    Key message: Conventional transbronchial needle aspiration (cTBNA) remains a basic technique that must be part of the bronchoscopists expertise. In cases where EBUS is not available, cTBNA must be kept in mind: ‘the old bull knows best’.

  • Open Access

    Persistent alveolar air leak following pulmonary lobectomy: an old problem in a modern era

    by Dario Amore, Umberto Caterino, Dino Casazza, Riccardo Ievoli, Pasquale Imitazione, Alessandro Saglia, Alessandro Izzo, Marco Rispoli, Carlo Curcio

    Persistent alveolar air leak (PAAL) after major lung resection remains a common complication in thoracic surgery. The aim of this study was to identify a subset of patients with high risk of developing PAAL after pulmonary lobectomy. Another objective was to evaluate the influence of PAAL on postoperative complications and length of hospital stay. A retrospective analysis on 895 patients undergoing pulmonary lobectomy from January 2014 to December 2019 was performed. PAAL was defined as air leak lasting more than 5 days after lung surgery. Univariate analyses and logistic regressions were performed to identify the predictors of PAAL. A backward selection algorithm was used to identify the optimal set of predictors. The incidence of PAAL was 8.2% (74/895). Male gender (p=0.017), BMI (p<0.001), transient ischemic attack (p=0.031), FEV1 (p=0.018), lobectomy combined with adjacent subsegmentectomy (p=0.018), partial and extended pleural adhesions (p=0.033 and p=0.038, respectively) were identified as independent risk factors for PAAL through logistic regression. A weak positive correlation was found between video-assisted thoracic surgery (VATS) and PAAL following pulmonary lobectomy (p=0.100). PAAL was found to be associated with higher risk of postoperative morbidity (p=0.002) and with longer hospital stay (p<0.001). Both preoperative and intraoperative risk factors may be responsible for PAAL after pulmonary lobectomy. VATS does not appear to prevent this postoperative complication. An alveolar air leak lasting beyond 5 days after pulmonary lobectomy is associated with worse postoperative outcomes.


  • Open Access

    Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report

    by Cristiano Cesaro, Umberto Caterino, Fabio Perrotta, Umberto Masi, Alessandra Cotroneo, Roberta Cianci, Enzo Zamparelli, Flavio Cesaro, Dario Amore, Danilo Rocco

    Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.

  • Open Access

    Anomalous segmental pulmonary vein: additional V6 behind the bronchus intermedius draining into the superior pulmonary vein

    by Dario Amore, Emanuele Muto, Umberto Caterino, Dino Casazza, Alessandro Saglia, Pasquale Imitazione, Carlo Curcio

    Anatomical variations of pulmonary venous drainage have been widely described in the literature in order to perform safe thoracic surgical procedures. We report a case of anomalous vein from the superior segment of the right lower lobe running in the posterior mediastinum and draining into the superior pulmonary vein. As the patient showed a usual right inferior pulmonary vein, formed by the union of the superior segment right lower lobe vein (V6) and the common basal vein joining the left atrium, the uncommon segmental pulmonary vein described was named: additional V6. It was identified preoperatively and recognized intraoperatively during thoracoscopic right lower lobectomy and lymph node dissection performed for lung cancer treatment. Diagnostic imaging and careful surgical dissection are helpful tools to avoid intraoperative bleeding and other complications during thoracic surgical procedures due to unrecognized vascular anomalies.


  • Open Access

    Unusual Periaortic Mediastinal Recurrence of Pulmonary Adenocarcinoma: When Making Diagnosis Is Really Necessary

    by Umberto Caterino, Dario Amore, Cristiano Cesaro, Enzo Zamparelli, Flavio Cesaro, Alba Palma, Marcellino Cicalese, Dino Casazza, Raffaella Lucci, Alessandra Cancellieri

    We report an unusual mediastinal recurrence along descending thoracic aorta during oncologic follow-up in a 47-year-old female smoker issued by lung adenocarcinoma with a history of left lower lobectomy and lingulectomy en bloc followed by adjuvant chemotherapy for stage III A-N2. Regional recurrence occurring along the staple line was suspected and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) combined to PET/CT allowed to reach definitive tissue diagnosis. High focal hypermetabolic activity on PET/CT at the site of suspect recurrence was necessary to check the lesion sampling by EBUS-TBNA.

  • Open Access

    Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”

    by Umberto Caterino, Cristiano Cesaro, Enzo Zamparelli, Flavio Cesaro, Alba Palma, Raffaella Lucci, Pasquale Imitazione, Dino Casazza, Dario Amore

    Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2 young women showing malignant pleural effusion secondary to advanced ALK-rearranged lung adenocarcinoma. This report shows that for patients with EGFR mutations in advanced lung adenocarcinoma-associated malignant pleural effusion, complete response to EGFR TKI inhibitor can be observed mostly if pleural effusion and primary lung adenocarcinoma show the same EGFR mutation status.